As CFO and COO of Provectus Pharmaceuticals, Inc., Peter Culpepper helps lead a Knoxville, Tennessee, company focused on developing new therapies in the dermatology and oncology spheres. Peter Culpepper and his team are currently working on the novel injectable cancer drug PV-10, which is moving through the clinical investigative stages.

1. RESEARCH POINTS TO
PV-10 AS A POTENTIAL
TREATMENT FOR COLON
CANCER
Peter Culpepper

2. Introduction
 As CFO and COO of Provectus Pharmaceuticals,
Inc., Peter Culpepper helps lead a Knoxville,
Tennessee, company focused on developing new
therapies in the dermatology and oncology
spheres. Peter Culpepper and his team are
currently working on the novel injectable cancer
drug PV-10, which is moving through the clinical
investigative stages.
As reported in a February 2016 presentation at
the 11th Annual Academic Surgical Congress,
new research points to PV-10 being effective in
causing potent immunogenic apoptosis in cells
with colon cancer.

3. Colon Cancer
 This finding is consistent with cytotoxicity
associated with cancer cell death induced by a
cytostatic agent.
The presenter of the data, Dr. N. M. Kunda of the
University of Illinois at Chicago, explained that
observations of autophagy, cell arrest, apoptosis,
and endoplasmic reticulum stress were in line with
the initial finding. Commenting on the
presentation, a Provectus executive noted that the
research has expanded the understanding of PV-
10 as a mechanism for addressing solid tumors
through an ablative immunotherapy approach.